|
gptkbp:instance_of
|
gptkb:pharmaceuticals
gptkb:chemical_compound
|
|
gptkbp:affects
|
hallucinations
|
|
gptkbp:approves
|
not approved for general use
|
|
gptkbp:availability
|
limited availability
prescription only
research chemicals
|
|
gptkbp:brand
|
gptkb:Chew-Z
|
|
gptkbp:can_be_used_to
|
gptkb:psychotherapy
|
|
gptkbp:chemical_formula
|
C20 H24 N2 O2
C20 H25 N3 O2 S
C20 H24 N2 O2 S
|
|
gptkbp:class
|
tryptamines
phenothiazines
antipsychotic
|
|
gptkbp:clinical_trial
|
conducted
ongoing studies
|
|
gptkbp:clinical_use
|
experimental use
|
|
gptkbp:commissioned
|
1990s
|
|
gptkbp:composed_by
|
gptkb:chemical_compound
organic chemistry
laboratory techniques
requires specific precursors
|
|
gptkbp:contraindication
|
hypersensitivity to ingredients
|
|
gptkbp:cultural_significance
|
emerging interest in psychedelics
|
|
gptkbp:developed_by
|
gptkb:United_States_Army
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:discovered_by
|
gptkb:Dr._David_E._Nichols
|
|
gptkbp:discovery_year
|
1990s
|
|
gptkbp:dosage_form
|
oral tablet
|
|
gptkbp:drug_interactions
|
CNS depressants
|
|
gptkbp:duration
|
4-6 hours
|
|
gptkbp:field_of_study
|
pharmacology
|
|
gptkbp:formulation
|
gptkb:tablet
|
|
gptkbp:funding
|
military funding
|
|
gptkbp:future_prospects
|
clinical trials
long-term effects
safety studies
mechanism of action
potential therapeutic applications
|
|
gptkbp:historical_use
|
none documented
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Chew-Z
|
|
gptkbp:ingredients
|
Chew-Z compound
|
|
gptkbp:invention
|
patented
not patented
|
|
gptkbp:is_similar_to
|
other tryptamines
|
|
gptkbp:legal_status
|
varies by country
controlled substance
|
|
gptkbp:market_position
|
limited
|
|
gptkbp:marketed_as
|
gptkb:Chew-Z_brand
|
|
gptkbp:mechanism_of_action
|
serotonin receptor agonist
|
|
gptkbp:notable_work
|
may affect mood
may alter perception
may enhance creativity
may have therapeutic potential
may induce mystical experiences
|
|
gptkbp:pharmacokinetics
|
oral bioavailability
CNS depressant
|
|
gptkbp:production_status
|
experimental phase
|
|
gptkbp:provides_guidance_on
|
not established
|
|
gptkbp:publication
|
gptkb:academic_journals
|
|
gptkbp:regulatory_compliance
|
not approved by FDA
|
|
gptkbp:related_products
|
gptkb:DMT
gptkb:psilocybin
LSD
|
|
gptkbp:related_to
|
gptkb:depression
sleep aids
|
|
gptkbp:reports_to
|
individual variability
potential for misuse
varied experiences
dose-dependent effects
subjective effects
|
|
gptkbp:research_areas
|
psychedelic research
|
|
gptkbp:research_focus
|
sleep enhancement
|
|
gptkbp:research_institutes
|
gptkb:Walter_Reed_Army_Institute_of_Research
|
|
gptkbp:research_output
|
promising results
|
|
gptkbp:research_status
|
ongoing
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_features
|
not well established
not fully established
|
|
gptkbp:safety_measures
|
monitor for side effects
|
|
gptkbp:side_effect
|
anxiety
dizziness
nausea
drowsiness
constipation
dry mouth
weight gain
blurred vision
potential for abuse
|
|
gptkbp:structure
|
complex organic compound
|
|
gptkbp:target_audience
|
gptkb:military_personnel
|
|
gptkbp:target_receptors
|
5-HT2 A receptors
|
|
gptkbp:targets
|
insomnia
|
|
gptkbp:therapeutic_category
|
sleep medication
|
|
gptkbp:type
|
gptkb:pharmaceuticals
|
|
gptkbp:used_for
|
treatment of sleep disorders
treating schizophrenia
|
|
gptkbp:user_experience
|
varied effectiveness
|
|
gptkbp:weight
|
324.42 g/mol
|